Atlas Trials

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Clinical trial NCT03514017 · TERMINATED

Trial details

NCT number
NCT03514017
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2019-05-31
Primary completion
2023-05-16
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.